Sosman JA - Search Results

1

RAF265 inhibits the growth of advanced human melanoma tumors.

Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A. Su Y, et al. Among authors: sosman ja. Clin Cancer Res. 2012 Apr 15;18(8):2184-98. doi: 10.1158/1078-0432.CCR-11-1122. Epub 2012 Feb 20. Clin Cancer Res. 2012. PMID: 22351689 Free PMC article.

2

Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma.

Clark JI, Gaynor ER, Martone B, Budds SC, Manjunath R, Flanigan RC, Waters WB, Sosman JA. Clark JI, et al. Among authors: sosman ja. Clin Cancer Res. 1999 Sep;5(9):2374-80. Clin Cancer Res. 1999. PMID: 10499607 Clinical Trial.

3

Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.

Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A. Amiri KI, et al. Among authors: sosman ja. Cancer Res. 2004 Jul 15;64(14):4912-8. doi: 10.1158/0008-5472.CAN-04-0673. Cancer Res. 2004. PMID: 15256463

4

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.

Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA. Wyman K, et al. Among authors: sosman ja. Cancer. 2006 May 1;106(9):2005-11. doi: 10.1002/cncr.21834. Cancer. 2006. PMID: 16565971 Free article. Clinical Trial.

5

Molecular targets in melanoma from angiogenesis to apoptosis.

Sosman JA, Puzanov I. Sosman JA, et al. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2376s-2383s. doi: 10.1158/1078-0432.CCR-05-2558. Clin Cancer Res. 2006. PMID: 16609062 Review.

6

The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.

Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML. Hande KR, et al. Clin Cancer Res. 2006 May 1;12(9):2834-40. doi: 10.1158/1078-0432.CCR-05-2159. Clin Cancer Res. 2006. PMID: 16675578 Clinical Trial.

7

Opportunities and obstacles to combination targeted therapy in renal cell cancer.

Sosman JA, Puzanov I, Atkins MB. Sosman JA, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):764s-769s. doi: 10.1158/1078-0432.CCR-06-1975. Clin Cancer Res. 2007. PMID: 17255307 Review.

8

Combination targeted therapy in advanced renal cell carcinoma.

Sosman J, Puzanov I. Sosman J, et al. Cancer. 2009 May 15;115(10 Suppl):2368-75. doi: 10.1002/cncr.24234. Cancer. 2009. PMID: 19402058 Free article. Review.

9

Inside life of melanoma cell signaling, molecular insights, and therapeutic targets.

Sosman JA, Margolin KA. Sosman JA, et al. Curr Oncol Rep. 2009 Sep;11(5):405-11. doi: 10.1007/s11912-009-0054-y. Curr Oncol Rep. 2009. PMID: 19679016 Review.

10

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP. Lockhart AC, et al. Among authors: sosman ja. J Clin Oncol. 2010 Jan 10;28(2):207-14. doi: 10.1200/JCO.2009.22.9237. Epub 2009 Nov 30. J Clin Oncol. 2010. PMID: 19949018 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

356 results

Search Page